Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
Answer from: Medical Oncologist at Community Practice
I avoid the issue by taking a sequential approach. I typically start premenopausal women on tamoxifen, then add OFS 4-6w later depending on their tolerance of tamoxifen, and then change to an AI after another 6-12 weeks.
It is easy to underestimate the severity of side effects that many premenopaus...
Comments
Medical Oncologist at Providence Hospital and Medical Centers Thank you @Eric C. Anderson. That is very helpful.
Medical Oncologist at Rochester Regional Health/Unity Hospital (Rochester) Drs. @Howard and @Henry, Oncology fellow here - In...
Medical Oncologist at University of Michigan Medical School Correct, you would not want to use aromatase inhib...
Answer from: Medical Oncologist at Community Practice
I check hormone levels to confirm the efficacy of ovarian suppression – but not specifically prior to adding an aromatase inhibitor. For example, in the TREND trial, it took a median of 14 days to achieve estradiol <2.7 pg/mL, and all patients achieved optimal ovarian suppression by the end...
Comments
Medical Oncologist at Providence Hospital and Medical Centers Thank you Dr. @Howard. My original question was ho...
Answer from: Medical Oncologist at Academic Institution
For patients who are starting GnRH agonist therapy, I routinely check hormone levels to confirm ovarian suppression before adding an aromatase inhibitor. A small proportion of patients do not achieve suppression of ovarian function (Bellet et al., PMID 26729437), although the clinical implications o...
Thank you @Eric C. Anderson. That is very helpful.
Drs. @Howard and @Henry, Oncology fellow here - In...
Correct, you would not want to use aromatase inhib...